Nicholas Vogelzang, MD, on Urothelial Cancer: Lenvatinib Plus Pembrolizumab

Posted: Tuesday, March 5, 2019

Nicholas Vogelzang, MD, of the Comprehensive Cancer Centers of Nevada, discusses how the combination of lenvatinib and pembrolizumab may fit into the future treatment landscape for patients with urothelial cancer.